Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Finviz2026/04/14 12:06

By:Finviz

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Adds dedicated business development leadership to support Tempest’s strategic priorities
Will lead China outreach and cross-border partnership efforts
To support ongoing partnering discussions for Phase 3-ready amezalpat program, including potential China development opportunities

BRISBANE, Calif., April 14, 2026 -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the appointment of Andrew Fang, Ph.D., as Head of Business Development. Dr. Fang will lead Tempest’s global business development efforts, including strategic partnerships, cross-border licensing and corporate transactions, with a particular focus on expanding Tempest’s outreach and partnering efforts in China.

The appointment reflects Tempest’s increasing emphasis on business development as a core strategic priority, including pursuing potential partnerships for its Phase 3-ready small molecule program, amezalpat, and advancing strategic collaborations across its CAR-T portfolio.

“We are pleased to welcome Andrew to the Tempest team,” said Dr. Matt Angel, President and Chief Executive Officer of Tempest. “Andrew brings deep experience in cross-border licensing, strategic transactions and capital markets, particularly across the United States and Chinese biotech ecosystems. As we prioritize business development, including seeking a partner for our Phase 3-ready amezalpat program and pursuing Chinese development opportunities following regulatory clearance for a pivotal trial, we believe Andrew’s expertise and relationships will be invaluable.”

Tempest continues to prioritize strategic partnerships for amezalpat, its Phase 3-ready small molecule program for hepatocellular carcinoma (“HCC”). Tempest previously announced clearance to proceed with a pivotal trial of amezalpat in China, building on alignment with the U.S. Food and Drug Administration (“FDA”) and European Medical Agency (“EMA”) on amezalpat’s Phase 3 study design and positioning the program for potential global development. Tempest believes that these regulatory milestones also create opportunities for regional partnerships and cross-border collaborations.

Dr. Fang is a Founding Partner and Principal of YQ Advisors, where he focuses on strategic transactions and value creation in biotechnology and emerging technologies. He brings extensive experience across cross-border licensing, asset transactions, biotech financing and public-company strategic initiatives.

“I am excited to join Tempest at this important stage,” said Dr. Fang. “Tempest has built a compelling portfolio, including a Phase 3-ready asset in amezalpat with regulatory clearance to pursue a pivotal study, and an emerging CAR-T platform. I look forward to helping the company advance its business development strategy and pursue partnerships that maximize value for patients and shareholders.”

At YQ Advisors, Dr. Fang has focused on ex-China/global licensing, M&A and reverse merger opportunities involving public biotechnology companies, as well as incubation of early-stage biotechnology platforms, particularly in cell and gene therapy and AI-enabled biotechnology. Dr. Fang has developed substantial experience in the cell and gene therapy space, with an emphasis on CAR-T, and brings strong connectivity to Chinese biotech clinical resources, strategic investors and potential operating partners, to support the evaluation, development and strategic positioning of innovative therapeutic programs in this area.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer. Tempest is focused on advancing both small molecule and cell therapy programs, including amezalpat, a Phase 3-ready small molecule candidate for hepatocellular carcinoma, and a portfolio of dual-targeting CAR-T programs. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at https://www.tempesttx.com.

Forward-Looking Statements

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

1. U.S. equities gained over the week, while crypto assets declined, reflecting a divergence in risk appetite. From October 3 to 9, the S&P 500 rose 1.15% and the Nasdaq 100 gained 0.24%, while BTC, ETH, and SOL fell 2.31%, 6.84%, and 7.99%, respectively. The U.S. Dollar Index advanced 0.27%, and although the 10-year U.S. Treasury yield declined 3.3 basis points, it remained elevated at 5.244%. High funding costs therefore continued to weigh on risk asset valuations. 2. Weak employment data have not eliminated inflation concerns, while AI and on-chain finance face growing scrutiny over commercial viability. September nonfarm payrolls increased by just 29,000, yet the minutes of the Federal Reserve's September meeting still pointed to the possibility of further rate hikes before year-end. This week's CPI release and major bank earnings will provide important tests of growth and inflation pressures. Revenue recognition and reporting practices in AI, underlying asset rights in RWA, and operating costs for Layer 2 networks are also becoming increasingly important measures of commercial viability. 3. Bitget has completed its phased service restoration, while the Bitget Alliance Program continues to support clients' trading and capital management needs. We completed the planned restoration on October 2 and replenished the Protection Fund to more than $300 million on September 30. According to DefiLlama, assets tracked on the platform rebounded from approximately $5.647 billion on October 1 to $6.223 billion on October 11. This report also outlines VIP level protection, user rewards, and institutional fee incentives to help high-value clients plan their trading activities according to their account type. Assets to watch: BTC, ETH, SOL, SUI, PUMP, gold, JPM, BAC, and ASML. Key areas of focus this week: The October 14 U.S. CPI release; bank net interest income and credit costs; AI cash flow generation; and post-recovery trends in assets held on Bitget, settlement efficiency, and trading conditions. Market data are current through October 9 or the latest local trading day. Official announcements and promotion terms were reviewed through October 12.

Bitget•2026/10/13 07:46